MIL62
MIL62 is a glycoengineered type II anti-CD20 monoclonal antibody with a nearly completely afucosylated N-glycans in Fc region. MIL62 shows enhanced affinity for the FcγRIIIa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) [1].
Product Specifications
UNSPSC
12352203
Target
CD20
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Shi Y, et al. Efficacy and safety of MIL62, a novel glycoengineered type II anti-CD20 monoclonal antibody, combined with lenalidomide in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma: a multicentre, single-arm, phase 1b/2 trial. EClinicalMedicine. 2024 Jun 20;73:102702.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS7142540 Inquire
Rabbit anti-Drosophila melanogaster (Fruit fly) gammaTub23C Polyclonal Antibody
Sign In for Pricing
View Details 
bs-11725R-PE-Cy5.5 100 µL
GDAP1 Polyclonal Antibody, PE-Cy5.5 Conjugated
Sign In for Pricing
View Details